Valerie A. Flores, MD Clinical Instructor Division of Reproductive Endocrinology & Infertility Department of Obstetrics, Gynecology & Reproductive Sciences Yale School of Medicine - Yale New Haven Hospital

Endometriosis: Biomarker May Allow Personalized Approach to Treatment

MedicalResearch.com Interview with:

Valerie A. Flores, MD Clinical Instructor Division of Reproductive Endocrinology & Infertility Department of Obstetrics, Gynecology & Reproductive Sciences Yale School of Medicine - Yale New Haven Hospital

Dr. Flores

Valerie A. Flores, MD
Clinical Instructor
Division of Reproductive Endocrinology & Infertility
Department of Obstetrics, Gynecology & Reproductive Sciences
Yale School of Medicine – Yale New Haven Hospital

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: Endometriosis is a debilitating gynecologic disease that affects 1 in 10 reproductive-aged women, causing pain and infertility.  It is a hormonally dependent disorder— estrogens promote growth of endometriosis, while progesterone inhibits estrogen-dependent proliferation. Although progestin-based therapies (including combined oral contraceptives) are first-line therapy in the management of endometriosis-associated pain, response to progestins is variable and currently unpredictable.

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: A test that predicts response to progestin-based therapy would allow for a personalized approach to treating endometriosis. We found that Progesterone Receptor (PR) status in endometriotic lesions is strongly associated with response to progestin-based therapy. 

MedicalResearch.com: What should readers take away from your report?

Response: Receptor status in endometriosis could be used in a manner analogous to the use of ER/PR status in breast cancer for tailoring hormonal-based regimens. Such an approach to endometriosis management would negate trialing progestin-based therapy to determine response, and minimize delays in providing the optimal medical therapy for each individual patient. The utilization of PR status in endometriotic lesions may allow for a novel, targeted approach to treating endometriosis.

 Citation:

Valerie A Flores, Arne Vanhie, Tran Dang, Hugh S Taylor; Progesterone Receptor Status Predicts Response to Progestin Therapy in Endometriosis, The Journal of Clinical Endocrinology & Metabolismhttps://doi.org/10.1210/jc.2018-01227 

Oct 25, 2018 @ 11:13 am

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

 

No Comments

Post A Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.